Your free registration includes the full conference, but feel free to join the sessions that work with your schedule. Agenda and details subject to change.
Agenda
CME/CE Accredited Session
Non-CME/CE
Session
Sponsored by
Industry
Click For Session
Details
Session
Times Listed in ET
8–9:15am ET
Beyond Statins: The Dawn of a New Era for Reducing LDL-Associated Risk for ASCVD
Christie M. Ballantyne, MD, FACP, FACC | Kevin Maki, PhD, CLS, FNLA, FTOS, FACN
National lipid expert faculty will discuss the incidence of and diagnostic criteria for statin intolerance, explain the mechanistic rationale for lowering LDL-C through nonstatin therapies, explore novel targets and treatment pathways, and apply the 2018 AHA/ACC Cardiology Cholesterol Guidelines. Learners will gain practical clinical perspectives during expert case study discussions, including how new treatment options may fit into the current therapeutic landscape.
Christie M. Ballantyne, MD, FACP, FACC
Professor of Medicine, Molecular & Human Genetics, and Molecular Physiology & Biophysics, Chief of Cardiology & Cardiovascular Research, Director, Center for Cardiometabolic Disease Prevention, Baylor College of Medicine, Houston, TX
Kevin Maki, PhD, CLS, FNLA, FTOS, FACN
Midwest Biomedical Research, a Division of MB Clinical Research and Consulting LLC., Indiana University School of Public Health, Bloomington, IN
Supported by Esperion Therapeutics, Inc.
9:25–10:25am ET
Cardiology and COVID-19: What Do We Need to Know?
Peter Libby, MD
With the COVID-19 pandemic moving through the country, it is important for clinicians to have the most up-to-date information. Join this session with Dr. Peter Libby to learn about the cardiovascular complications of COVID-19 and how you can help patients facing these issues.
Peter Libby, MD
Cardiovascular Medicine Specialist, Brigham and Women's Hospital, Mallinckrodt Professor of Medicine, Harvard Medical School, Boston, MA
10:35–11:20am ET
Hameed Ali, DO, SFHM
Prevalence of heart failure (HF) is on the rise. Patients hospitalized with heart failure with reduced ejection fraction (HFrEF) are at considerable risk for readmission and mortality. This program will review the opportunity to reassess and influence the trajectory of these patients’ disease through inpatient initiation of a medication shown to help prevent rehospitalization due to HFrEF, reduce patient CV mortality, and improve patients’ quality of life. This program will review mechanistic evidence and provide rationale for its in-hospital initiation.
Hameed Ali, DO, SFHM
Hospitalist, Baylor Scott & White Health, Clinical Assistant Professor (Affiliated), Texas A&M University Health Science Center College of Medicine, Temple, TX
Sponsored by Novartis Pharmaceuticals Corporation
10:35–11:20am ET
Jardiance® (empagliflozin) tablets: A Review of Multiple Clinical Trials and Approved Indications
Eugene E. Wright Jr, MD
This program will review multiple clinical trials and approved indications for JARDIANCE. The presentation will cover efficacy and safety data, as well as the dosing information for JARDIANCE. Attendees will also have the opportunity to ask the faculty questions about the data presented.
Eugene E. Wright Jr, MD
Medical Director, Performance Improvement Charlotte Area Health Education Center (AHEC) Charlotte, North Carolina
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC
11:30am–12:45pm ET
Advances and Strategies in Lipid Management to Prevent ASCVD Events
Peter Libby, MD | Michael Miller, MD, FACC, FAHA
This session will review the recent cardiovascular outcomes trials and their clinical implications in reducing ASCVD events. The expert faculty will also discuss the practical usage of therapies targeting ASCVD event reduction as adjuncts to statin therapy to reduce residual ASCVD risk.
Peter Libby, MD
Cardiovascular Medicine Specialist, Brigham and Women's Hospital, Mallinckrodt Professor of Medicine, Harvard Medical School, Boston, MA
Michael Miller, MD, FACC, FAHA
Professor of Cardiovascular Medicine, Director, Center for Preventive Cardiology, University of Maryland School of Medicine, Baltimore, MD
Supported by Amarin Pharma Inc.
12:55–1:40pm ET
Atherosclerotic Cardiovascular Disease (ASCVD) High Risk Assessment, Evaluation, and Management
James Underberg, MD
This program highlights the burden of cardiovascular disease in high-risk patients, focusing on the association between LDL- C and ASCVD risk and the importance of lowering LDL-C levels.
The use of LDL-C– lowering therapies to reduce risk in high-risk patients, such as patients with diabetes, is described with considerations from the current environment.
James Underberg, MD
Clinical Assistant Professor, Department of Medicine, NYU Grossman School of Medicine, New York, NY
Sponsored by Novartis Pharmaceuticals Corporation
12:55–1:40pm ET
Personalizing Inhaled Therapy and Inhaler Choice for COPD Management
Robert Keith, MD
Early and accurate diagnosis of chronic obstructive pulmonary disease (COPD) followed by optimal management are very important. This educational activity, will discuss the diagnosis of COPD, goals for treatment, pharmacological management, and the role of inhaled therapy and inhaler choice in the management of patients with COPD.
Robert Keith, MD
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.